surmount-1 trial tirzepatide non-diabetic weight loss once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 Retatrutide produces up to 30.3%

1 X Rybelsus is a GLP-1 receptor agonist containing semaglutide as the active ingredient

Its particularly beneficial for individuals dealing with metabolic issues, such as insulin resistance, where enhanced results might be needed

Ongoing mental health monitoring remains best practice

Galectin-9 is a possible promoter of immunopathology in rheumatoid arthritis by activation of peptidyl arginine deiminase 4 (pad-4) in granulocytes

Funding This research was supported by the Arkansas Biosciences Institute (Little Rock, AR, USA), The Jonty Foundation (St Paul, MN), The Autism Research Institute (San Diego, CA), the Gupta Family Foundation (Atherton, CA), The Jane Bostford Johnson Foundation (New York, NY) and the Jager Family Foundation (Chicago, IL)

Enzymes involved in branched-chain amino acid metabolism in humans